ProSciento, Inc., a specialty clinical research organization (CRO) focused exclusively on diabetes, obesity, non-alcoholic steatohepatitis (NASH), and related metabolic diseases, has announced the appointment of Michelle Mazuranic, PhD, MSM, RD, as Vice President of Medical and Regulatory Affairs.
In this role, she oversees ProSciento’s medical affairs and regulatory consulting services, as well as works with clients to build strategic clinical development programs from early engagement assessment and planning through the completion of multi-site clinical trials.
“We are thrilled to have Michelle join our scientific leadership team. She is a widely recognized leader in global medical and scientific affairs, driving forward clinical development and regulatory strategies for new therapies in metabolic diseases. Michelle’s deep and highly applicable expertise, as well as her direct experience in metabolic diseases, further augments our clinical development consulting services for a rapidly growing global client base,” said Marcus Hompesch, MD, ProSciento’s CEO and Chairman of the Board.
“I’m pleased to join ProSciento’s highly respected scientific team and to have a leadership role in continuing to expand ProSciento’s global clinical development and regulatory services. ProSciento’s science-driven, therapeutically focused expertise is unique and differentiating within the CRO industry, leading to meaningful outcomes for our clients’ metabolic drug and device development programs, as well as for patients by accelerating promising IND candidates through phase II/III studies,” said Dr. Mazuranic.
Dr. Mazuranic has extensive experience in building and leading global scientific strategies for clinical development, regulatory and medical affairs. Prior to joining ProSciento, Dr. Mazuranic served as Head of Global Medical Affairs at Gan & Lee Pharmaceuticals, where she built the department from the ground up. Prior to that, she served as Director of Global Medical Affairs for the Cardio-Renal and Metabolism Team for a seven-year tenure at AstraZeneca, where she managed strategic relationships with external scientific, academic, and advocacy group organizations and experts. Throughout her career, Dr. Mazuranic has developed and implemented activities to support global and compound-specific strategies, external scientific engagement, medical excellence, and evidence generation. Dr. Mazuranic is a licensed dietitian, completed her MS in management from Boston University, and earned her PhD in Public Health and Epidemiology from Walden University.
About ProSciento, Inc.
ProSciento is the leading specialized CRO focused on NASH, diabetes, obesity, and related metabolic diseases. The company works with biopharma companies worldwide to support their outsourced clinical research needs with comprehensive and customized services for multinational, early development clinical trial programs. Founded in 2003, ProSciento has conducted more than 350 clinical studies for diabetes, NASH, and obesity, and has contributed to the development of numerous approved metabolic drugs and devices on the global marketplace. For more information, please visit www.prosciento.com.
For business development inquiries, please contact:
For media inquiries, please contact:
Senior Director, Corporate Communications, ProSciento, Inc.